Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients

Campana, Raffaela; Moritz, Katharina; Neubauer, Angela; Huber, Hans; Henning, Rainer; Brodie, Tess M.; Kaider, Alexandra; Sallusto, Federica; Wöhrl, Stefan; Valenta, Rudolf

doi:10.1038/s41598-017-10278-1

Back

Journal article

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients

Campana, Raffaela Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
Moritz, Katharina Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
Neubauer, Angela Biomay AG, Vienna Competence Center, Vienna, Austria
Huber, Hans Biomay AG, Vienna Competence Center, Vienna, Austria
Henning, Rainer Biomay AG, Vienna Competence Center, Vienna, Austria
Brodie, Tess M. Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
Kaider, Alexandra Center for Medical Statistics, Informatics and Intelligent Systems, Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria
Sallusto, Federica Institute for Research in Biomedicine (IRB), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Institute of Microbiology, ETH Zuerich, Switzerland
Wöhrl, Stefan Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
Valenta, Rudolf Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria

14.09.2017

Published in:

Scientific reports. - 2017, vol. 7, p. 11657

English The effects of epicutaneous allergen administration on systemic immune responses in allergic and non-allergic individuals has not been investigated with defined allergen molecules. We studied the effects of epicutaneous administration of rBet v 1 and rBet v 1 fragments on systemic immune responses in allergic and non-allergic subjects. We conducted a clinical trial in which rBet v 1 and two hypoallergenic rBet v 1 fragments were applied epicutaneously by atopy patch testing (APT) to 15 birch pollen (bp) allergic patients suffering from atopic dermatitis, 5 bp-allergic patients suffering from rhinoconjunctivitis only, 5 patients with respiratory allergy without bp allergy and 5 non-allergic individuals. Epicutaneous administration of rBet v 1 and rBet v 1 fragments led to strong and significant increases of allergen-specific T cell proliferation (CLA+ and CCR4+T cell responses) only in bp-allergic patients with a positive APT reaction. There were no relevant changes of Bet v 1-specific IgE and IgG responses. No changes were noted in allergic subjects without bp allergy and in non-allergic subjects. Epicutaneous allergen application boosts specific T cell but not antibody responses mainly in allergic, APT-positive patients suggesting IgE-facilitated allergen presentation as mechanism for its effects on systemic allergen-specific immune responses.

Language